Premium
Satisfaction of treatment with biologics is high in psoriasis: results from the Bio‐ CAPTURE network
Author(s) -
Reek J.M.P.A.,
Lüumig P.P.M.,
Otero M.E.,
Zweegers J.,
Kerkhof P.C.M.,
Ossenkoppele P.M.,
Njoo M.D.,
Mommers J.M.,
Koetsier M.I.A.,
Arnold W.P.,
SybrandyFleuren B.A.M.,
Kuijpers A.L.A.,
Andriessen M.P.M.,
Seyger M.M.B.,
Kievit W.,
Jong E.M.G.J.
Publication year - 2014
Publication title -
british journal of dermatology
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 2.304
H-Index - 179
eISSN - 1365-2133
pISSN - 0007-0963
DOI - 10.1111/bjd.12862
Subject(s) - medicine , ustekinumab , adalimumab , etanercept , patient satisfaction , physical therapy , psoriasis , disease , surgery , dermatology , rheumatoid arthritis
Summary Background Although the effectiveness of biologics for psoriasis has been measured extensively with objective outcome measures, studies based on subjective, patient‐reported outcome measures remain scarce. Objectives To investigate satisfaction with medication, as measured by the Treatment Satisfaction Questionnaire for Medication ( TSQM ) for biologics in daily practice psoriasis care in the first 6 months of treatment; and to identify possible differences in satisfaction with medication between patients experienced (biologics‐experienced) and inexperienced (biologics‐inexperienced) in the use of biologics. Methods TSQM baseline measurements were compared using measurements taken after 6 months, using the Wilcoxon signed‐rank test for paired comparisons. Intention‐to‐treat with last observation carried forward (ITT with LOCF) and as‐treated analyses were performed. The difference between biologics‐experienced and biologics‐inexperienced patients for TSQM was analysed using ITT with LOCF. At 6 months, outcomes for biologics‐experienced and biologics‐inexperienced patients were compared using the Mann–Whitney U ‐test. Results One hundred and six patients were eligible for analysis, and treated with etanercept ( n = 34), adalimumab ( n = 49) or ustekinumab ( n = 23). Fifty‐four per cent of patients were biologics‐inexperienced. A statistically significant improvement was seen in all domains of the TSQM (‘effectiveness’, ‘side‐effects’, ‘convenience’ and ‘global satisfaction’) by comparison of months 3 or 6 with baseline (all P ≤ 0·02). After 6 months, biologics‐inexperienced patients scored better on the ‘global satisfaction’ domain than biologics‐experienced patients ( P < 0·01). Conclusions We provide a prospective, longitudinal analysis of TSQM for biologics in daily practice psoriasis care. High satisfaction rates were achieved. The ‘effectiveness’ and ‘convenience’ domains showed the most room for improvement.